{"denoms":[{"counts":[{"groupId":"BG000","value":"268"},{"groupId":"BG001","value":"268"},{"groupId":"BG002","value":"536"}],"units":"Participants"}],"groups":[{"description":"Participants with Philadelphia chromosome-positive CML received bosutinib tablets at a dose of 400 mg, orally once daily in the core treatment phase of 12 months and continued the same treatment into the extension phase or followed up for safety for up to approximately 4 years, until the end of the study, treatment failure, unacceptable toxicity, death, or withdrawal of consent, whichever occurred first.","id":"BG000","title":"Bosutinib"},{"description":"Participants with Philadelphia chromosome-positive CML received imatinib tablets at a dose of 400 mg, orally once daily in the core treatment phase of 12 months and continued the same treatment into the extension phase or followed up for safety for up to approximately 4 years, until the end of the study, treatment failure, unacceptable toxicity, death, or withdrawal of consent, whichever occurred first.","id":"BG001","title":"Imatinib"},{"description":"Total of all reporting groups","id":"BG002","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"15.40","value":"50.8"},{"groupId":"BG001","spread":"14.43","value":"50.9"},{"groupId":"BG002","spread":"14.91","value":"50.9"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"112"},{"groupId":"BG001","value":"113"},{"groupId":"BG002","value":"225"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"156"},{"groupId":"BG001","value":"155"},{"groupId":"BG002","value":"311"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"}],"populationDescription":"Intent-to-treat population: All randomized participants with study drug assignments designated according to initial randomization."}